A patient in sub-Saharan Africa is diagnosed with both HIV and chronic hepatitis B (HBV). The chosen first-line ART regimen is TLD (tenofovir/lamivudi...

Question

A patient in sub-Saharan Africa is diagnosed with both HIV and chronic hepatitis B (HBV). The chosen first-line ART regimen is TLD (tenofovir/lamivudine/dolutegravir). Why is tenofovir particularly important in this patient?

Accepted Answer

Tenofovir (TDF) has dual antiviral activity against both HIV and HBV, providing simultaneous treatment; importantly, if TDF is discontinued without an alternative HBV-active agent, there is a risk of severe HBV flare

Answer

Tenofovir has no activity against HBV

Answer

Tenofovir cures HBV permanently

Answer

Tenofovir prevents HBV transmission to others

Answer

Tenofovir is only active against HBV, not HIV

uk-dtmh MCQ (SBA): TDF in HIV-HBV Co-infection

A patient in sub-Saharan Africa is diagnosed with both HIV and chronic hepatitis B (HBV). The chosen first-line ART regimen is TLD (tenofovir/lamivudine/dolutegravir). Why is tenofovir particularly important in this patient?